ALECTOR INC.

Alector showcased its transferrin receptor–based brain-carrier platform and lead Alzheimer’s candidate AL137, which is slated to enter a Phase I study with subcutaneous dosing in April. Preclinical data show markedly higher drug concentrations in the brain without a significant drop in red blood cells; AL137 is intended to provide full effector function with reduced anemia risk. The company is also advancing programs targeting tau, alpha-synuclein and GCase and is seeking partnerships for Parkinson’s assets, while Alzheimer programs continue to be developed internally. Alector noted usual development risks; the stock fell during the presentation and the company expects multiple clinical milestones within the next 12 months. » More on de.investing.com

GSK and Alector have halted joint tests of a dementia drug after a trial flop. The news triggered a marked decline in Alector's share price. No further details about the study or the consequences for Alector's development pipeline were given. » More on finanzen.net

Alector reports that the phase‑3 INFRONT‑3 study of latozinemab (AL001) in frontotemporal dementia due to a progranulin mutation did not meet its primary endpoint, prompting a sharp decline in the stock in after‑hours trading. Despite increases in plasma progranulin concentrations, secondary and exploratory endpoints showed no treatment‑related effects. Alector is halting the study extension and the continuation study with GSK, plans a workforce reduction of about 49%, and will focus on remaining programs such as Nivisnebart (AL101/GSK4527226) and BBB‑platform candidates AL137 and AL050. As of 30 September 2025 the company had approximately USD 291.1 million in cash, expected to last through 2027. » More on de.investing.com